Browsing by Author Ahn, SH

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 17 to 36 of 39 < previous   next >
TitleAuthor(s)Issue DateViews
 
Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study)
Proceeding/Conference:Journal of Hepatology
Sonneveld, MPark, JYSeto, WKWTanaka, YCarey, IPapatheodoridi, MZoulim, FAhn, SHDalekos, GHoener zu Siederdissen, CCornberg, MYuen, RMFAgarwal, KBoonstra, AButi, MPapatheodoridis, GMaasoumy, B
2020
31
 
Lower Pre-Treatment HBV DNA Levels Are Associated With Better Off-Treatment Outcomes After Nucleo(S)Tide Analogue Withdrawal In Patients With Chronic Hepatitis B
Proceeding/Conference:Hepatology
Sonneveld, MJChiu, SMPark, JYBrakenhoff, SKaewdech, ASeto, WKTanaka, YCarey, IPapatheodoridi, MColombatto, PVan Bommel, FBerg, TZoulim, FAhn, SHDalekos, GNErler, NSBrunetto, MWedemeyer, HCornberg, MYuen, MFAgarwal, KBoonstra, AButi, MPiratvisuth, TPapatheodoridis, GVChen, CHMaasoumy, B
31-Oct-2022
 
New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia
Journal:PLoS ONE
Nishida, NSawai, HKashiwase, KMinami, MSugiyama, MSeto, WKWYuen, RMFPosuwan, NPoovorawan, YAhn, SHHan, KHMatsuura, KTanaka, YKurosaki, MAsahina, YIzumi, NKang, JHHige, SIde, TYamamoto, KSakaida, IMurawaki, YItoh, YTamori, AOrito, EHiasa, YHonda, MKaneko, SMita, ESuzuki, KHino, KTanaka, EMochida, SWatanabe, MEguchi, YMasaki, NMurata, KKorenaga, MMawatari, YOhashi, JKawashima, MTokunaga, KMizokami, M
2014
79
 
No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.
Journal:BMC Med Genet
Sawai, HNishida, NMbarek, HMatsuda, KMawatari, YYamaoka, MHige, SKang, JHAbe, KMochida, SWatanabe, MKurosaki, MAsahina, YIzumi, NHonda, MKaneko, STanaka, EMatsuura, KItoh, YMita, EKorenaga, MHno, KMurawaki, YHiasa, YIde, TIto, KSugiyama, MAhn, SHHan, KHPark, JYYuen, RMFNakamura, YTanaka, YMizokami, MMizokami, MTokunaga, K
2012
71
 
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
Journal:Gut
Lai, CLAhn, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NHKweon, YOSohn, JHLee, JKim, JAHan, KHYuen, RMF
2013
111
 
A phase IIb study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B
Proceeding/Conference:Hepatology
Lai, CLAhn, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NWKwon, YOSohn, JHLee, JYPark, HEKim, JAHan, KHYuen, MF
2011
97
 
Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – a multicenter study (CREATE)
Proceeding/Conference:Hepatology
Sonneveld, MJPark, JYKaewdech, ASeto, WKWTanaka, YCarey, IPapatheodoridi, MVan Bömmel, FBerg, TZoulim, FAhn, SHDalekos, GNErier, NSHöner zu SiederdissenC, CWedemeyer, HComberg, MYuen, RMFAgarwal, KBoonstra, AFerret, MABPiratvisuth, TPapatheodoridis, GMaasoumy, BCREATE study group,
2020
12
 
Prediction Of Sustained Response After Nucleo(s)tide Analogue Cessation Using Hbsag And Hbcrag Levels – A Multicenter Study (create)
Journal:Clinical Gastroenterology and Hepatology
Sonneveld, MJPark, JYKaewdech, ASeto, WKTanaka, YCarey, IPapatheodoridi, Mvan Bommel, FBerg, TZoulim, FAhn, SHDalekos, GNErler, NSHoner zu Siederdissen, CWedemeyer, HCornberg, MYuen, MFAgarwal, KBoonstra, AButi, MPiratvisuth, TPapatheodoridis, GMaasoumy, B
2020
36
 
Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels. Poster Presentation (SAT344)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Sonneveld1, MChiu, SMPark, JYKaewdech, ASeto, WKWTanaka, YCarey, IPapatheodoridi, Mvan Bömmel, FBrakenhoff, SBerg, TZoulim, FAhn, SHDalekos, GErler, NHoener zu Siederdissen, CWedemeyer1, HCornberg, MYuen, RMFAgarwa, KBoonstra, AButi, MPiratvisuth, TPapatheodoridis8, GChen, C-HMaasoumy, B
2022
1
 
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
Journal:Journal of Hepatology
Sonneveld, MJChiu, SMPark, JYBrakenhoff, SMKaewdech, ASeto, WKWTanaka, YCarey, IPapatheodoridi, Mvan Bommel, FBerg, TZoulim, FAhn, SHDalekos, GSErler, NSHoner zu Siederdissen, CWedemeyer, HCornberg, MYuen, RMFAgarwal, KBoonstra, AButi, MPiratvisuth, TPapatheodoridis, GChen, CHMaasoumy, B
2022
6
 
Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia
Journal:Journal of Hepatology
Chen, DSChen, PJLu, SNYang, PMSung, JLai, CLFung, JYYBae, SHLee, JSKim, HSAhn, SHYoon, GHTanaka, JWakita, TAizaki, HYonezawa, ALino, YAbe, YWard, JLou, LGore, CMohamed, RLocarnini, SWallace, JWait, SJohnston, J
2013
71
 
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score
Journal:The Lancet Oncology
Yang, HIYuen, MFChan, HLYHan, KHChen, PJKim, DYAhn, SHChen, CJWong, VWSSeto, WK
2011
155
 
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Journal:Hepatology
Yuen, MFSchiefke, IYoon, JHAhn, SHHeo, JKim, JHChan, HLYYoon, KTKlinker, HManns, MPetersen, JSchluep, THamilton, JGiven, BDFerrari, CLai, CLLocarnini, SAGish, RG
2020
20
 
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B
Journal:Hepatology Communications
Yuen, MFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, YSKim, YJPoovorawan, KTangkijvanich, PSchwabe, CEley, TBrown, JLee, ACHThi, EPParatala, BMani, NSofia, MJPicchio, GSims, KDGane, EJ
4-Oct-2022
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
31
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, Y-SKim, YJPoovorawan, KTangkijvanich, PChan, HLYEley, TBrown, JMoore, CLee, ACHKim, JThi, EPMani, NRijnbrand, RCole, ASofia, MJPicchio, GRSims, KGane, EJ
2019
48
 
Sofosbuvir (SOF) and ledipasvir (LDV) combination is associated with high sustained virologic response (SVR) and improvement of health-related quality of life (HRQL) in East Asian patients with hepatitis C virus (HCV) infection
Proceeding/Conference:Hepatology International
Younossi, ZStepanova, MHenry, LHan, KHAhn, SHLim, YSChuang, YLKao, JHKinh, NLai, CLYuen, RMFChan, HLYLai, W
2018
46
 
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection
Journal:Journal of Viral Hepatitis
YounossI, ZMStepanova, MHenry, LHan, HHAhn, SHLim, YSChuang, WLKao, JHNuguyen, KVLai, CLChan, HLYLai, W
2018
50
 
Telbivudine combination with adefovir versus adefovir monotherapy in HBeAg-positive chronic hepatitis B (CHB) patients with lamivudine resistance
Proceeding/Conference:Hepatology International
Ahn, SHKweon, YOPaik, SWSohn, JHLee, KSKim, DJPiratvisuth, TYuen, RMFTrylesinski, AAvila, C
2010
53
 
Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B
Journal:Hepatology International
Ahn, SHKweon, YOPaik, SWSohn, JHLee, KSKim, DJPiratvisuth, TYuen, MFChutaputti, AChao, YCTrylesinski, AAvila, C
2012
154
Showing results 17 to 36 of 39 < previous   next >